Portal de Periódicos da CAPES

Risks and Benefits of Repeated Courses of Intravesical Bacillus Calmette-guerin Therapy for Superficial Bladder Cancer

1987; Lippincott Williams & Wilkins; Volume: 137; Issue: 2 Linguagem: Inglês

10.1016/s0022-5347(17)43959-0

1527-3792

William J. Catàlona, M’Liss A. Hudson, Daniel Gillen, Gerald L. Andriole, Timothy L. Ratliff,

Urinary Tract Infections Management

No AccessJournal of Urology1 Feb 1987Risks and Benefits of Repeated Courses of Intravesical Bacillus Calmette-guerin Therapy for Superficial Bladder Cancer William J. Catalona, M'liss A. Hudson, Daniel P. Gillen, Gerald L. Andriole, and Timothy L. Ratliff William J. CatalonaWilliam J. Catalona , M'liss A. HudsonM'liss A. Hudson , Daniel P. GillenDaniel P. Gillen , Gerald L. AndrioleGerald L. Andriole , and Timothy L. RatliffTimothy L. Ratliff View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)43959-0AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail An actuarial analysis of the risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer was performed for 100 consecutive patients treated for carcinoma in situ (29), prophylaxis against recurrent tumor (51) or residual superficial papillary tumor (21). The risk-to-benefit ratio at entry into bacillus Calmette-Guerin therapy (7 per cent risk of invasive cancer developing, 5 per cent risk of metastases and 77 per cent prospect for status free of tumor) and in patients who had failed only 1 course of bacillus Calmette-Guerin therapy (11 per cent invasive cancer, 14 per cent metastases and 58 per cent free of tumor) were highly favorable. However, among patients who had failed 2 or more courses of bacillus Calmette-Guerin therapy the risks of invasive (30 per cent) or metastatic (50 per cent) cancer developing exceeded the prospects for eradicating the superficial tumor present (20 per cent) with further therapy. The results suggest that patients who have failed 2 courses of bacillus Calmette-Guerin therapy (as given in our treatment protocol) should be considered for alternative treatment. © 1987 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited ByMeng M, Gschwend J, Shore N, Grossfeld G, Mostafid H and Black P (2019) Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 202, NO. 6, (1111-1119), Online publication date: 1-Dec-2019.Haas C, Barlow L, Badalato G, DeCastro G, Benson M and McKiernan J (2018) The Timing of Radical Cystectomy for bacillus Calmette-Guérin Failure: Comparison of Outcomes and Risk Factors for PrognosisJournal of Urology, VOL. 195, NO. 6, (1704-1709), Online publication date: 1-Jun-2016.Chang S, Boorjian S, Chou R, Clark P, Daneshmand S, Konety B, Pruthi R, Quale D, Ritch C, Seigne J, Skinner E, Smith N and McKiernan J (2018) Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO GuidelineJournal of Urology, VOL. 196, NO. 4, (1021-1029), Online publication date: 1-Oct-2016.Morales A, Herr H, Steinberg G, Given R, Cohen Z, Amrhein J and Kamat A (2018) Efficacy and Safety of MCNA in Patients with Nonmuscle Invasive Bladder Cancer at High Risk for Recurrence and Progression after Failed Treatment with bacillus Calmette-GuérinJournal of Urology, VOL. 193, NO. 4, (1135-1143), Online publication date: 1-Apr-2015.McKiernan J, Holder D, Ghandour R, Barlow L, Ahn J, Kates M, Badalato G, Roychoudhury A, Decastro G and Benson M (2018) Phase II Trial of Intravesical Nanoparticle Albumin Bound Paclitaxel for the Treatment of Nonmuscle Invasive Urothelial Carcinoma of the Bladder after bacillus Calmette-Guérin Treatment FailureJournal of Urology, VOL. 192, NO. 6, (1633-1638), Online publication date: 1-Dec-2014.Barlow L, McKiernan J and Benson M (2018) Long-Term Survival Outcomes with Intravesical Docetaxel for Recurrent Nonmuscle Invasive Bladder Cancer After Previous Bacillus Calmette-Guérin TherapyJournal of Urology, VOL. 189, NO. 3, (834-839), Online publication date: 1-Mar-2013.Nativ O, Witjes J, Hendricksen K, Cohen M, Kedar D, Sidi A, Colombo R and Leibovitch I (2018) Combined Thermo-Chemotherapy for Recurrent Bladder Cancer After Bacillus Calmette-GuerinJournal of Urology, VOL. 182, NO. 4, (1313-1317), Online publication date: 1-Oct-2009.Hall M, Chang S, Dalbagni G, Pruthi R, Seigne J, Skinner E, Wolf J and Schellhammer P (2018) Guideline for the Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 UpdateJournal of Urology, VOL. 178, NO. 6, (2314-2330), Online publication date: 1-Dec-2007.DAVIS J, SHETH S, DOVIAK M and SCHELLHAMMER P (2018) SUPERFICIAL BLADDER CARCINOMA TREATED WITH BACILLUS CALMETTE-GUERIN: PROGRESSION-FREE AND DISEASE SPECIFIC SURVIVAL WITH MINIMUM 10-YEAR FOLLOWUPJournal of Urology, VOL. 167, NO. 2 Part 1, (494-501), Online publication date: 1-Feb-2002.Soloway M, Sofer M and Vaidya A (2018) Contemporary Management Of Stage T1 Transitional Cell Carcinoma Of The BladderJournal of Urology, VOL. 167, NO. 4, (1573-1583), Online publication date: 1-Apr-2002.GOMELLA L, MASTRANGELO M, McCUE P, MAGUIRE H, MULHOLLAND S and LATTIME E (2018) PHASE I STUDY OF INTRAVESICAL VACCINIA VIRUS AS A VECTOR FOR GENE THERAPY OF BLADDER CANCERJournal of Urology, VOL. 166, NO. 4, (1291-1295), Online publication date: 1-Oct-2001.O'DONNELL M, KROHN J and DeWOLF W (2018) SALVAGE INTRAVESICAL THERAPY WITH INTERFERON-α2B PLUS LOW DOSE BACILLUS CALMETTE-GUERIN IS EFFECTIVE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER IN WHOM BACILLUS CALMETTE-GUERIN ALONE PREVIOUSLY FAILEDJournal of Urology, VOL. 166, NO. 4, (1300-1305), Online publication date: 1-Oct-2001.WAIDELICH R, STEPP H, BAUMGARTNER R, WENINGER E, HOFSTETTER A and KRIEGMAIR M (2018) CLINICAL EXPERIENCE WITH 5-AMINOLEVULINIC ACID AND PHOTODYNAMIC THERAPY FOR REFRACTORY SUPERFICIAL BLADDER CANCERJournal of Urology, VOL. 165, NO. 6 Part 1, (1904-1907), Online publication date: 1-Jun-2001.PALOU J, LAGUNA P, MILLÁN-RODRÍGUEZ F, HALL R, SALVADOR-BAYARRI J and VICENTE-RODRÍGUEZ J (2018) CONTROL GROUP AND MAINTENANCE TREATMENT WITH BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU AND/OR HIGH GRADE BLADDER TUMORSJournal of Urology, VOL. 165, NO. 5, (1488-1491), Online publication date: 1-May-2001.KIM J and STEINBERG G (2018) THE LIMITS OF BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDERJournal of Urology, VOL. 165, NO. 3, (745-756), Online publication date: 1-Mar-2001.STEINBERG G, BAHNSON R, BROSMAN S, MIDDLETON R, WAJSMAN Z and WEHLE M (2018) EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDERJournal of Urology, VOL. 163, NO. 3, (761-767), Online publication date: 1-Mar-2000.NSEYO U, SHUMAKER B, KLEIN E and SUTHERLAND K (2018) PHOTODYNAMIC THERAPY USING PORFIMER SODIUM AS AN ALTERNATIVE TO CYSTECTOMY IN PATIENTS WITH REFRACTORY TRANSITIONAL CELL CARCINOMA IN SITU OF THE BLADDERJournal of Urology, VOL. 160, NO. 1, (39-44), Online publication date: 1-Jul-1998.Ovesen H, Horn T and Steven K (2018) Long-Term Efficacy of Intravesical Bacillus Calmette-Guerin for Carcinoma in Situ: Relationship of Progression to Histological Response and p53 Nuclear AccumulationJournal of Urology, VOL. 157, NO. 5, (1655-1659), Online publication date: 1-May-1997.Okamura T, Tozawa K, Yamada Y, Sakagami H, Ueda K and Kohri K (2018) Clinicopathological Evaluation of Repeated Courses of Intravesical Bacillus Calmette-Guerin Instillation for Preventing Recurrence of Initially Resistant Superficial Bladder CancerJournal of Urology, VOL. 156, NO. 3, (967-971), Online publication date: 1-Sep-1996.Hudson M (2018) Editorial: A New Staging System for Transitional Cell Carcinoma Involvement of the Prostate and Reconfirmation Studies of Intravesical Therapy for Superficial Bladder CancerJournal of Urology, VOL. 156, NO. 3, (972-974), Online publication date: 1-Sep-1996.de Reijke T, de Boer E, Kurth K and Schamhart D (2018) Urinary Cytokines During Intravesical Bacillus Calmetteguerin Therapy for Superficial Bladder Cancer: Processing, Stability and Prognostic ValueJournal of Urology, VOL. 155, NO. 2, (477-482), Online publication date: 1-Feb-1996.Schellhammer P, Ladaga L and Moriarty R (2018) Intravesical Bacillus Calmette-Guerin for Treatment of Superficial Transitional Cell Carcinoma of the Prostatic Urethra in Association With Carcinoma of the BladderJournal of Urology, VOL. 153, NO. 1, (53-56), Online publication date: 1-Jan-1995.Droller M (2018) A Commentary on Suramin Demonstrates in Vitro Toxicity against Transitional Cell Carcinoma Cell Lines and Exposure to Alkyllysophospholipids Inhibits in Vitro Invasion of Transitional Cell CarcinomaJournal of Urology, VOL. 152, NO. 5 Part 1, (1356-1357), Online publication date: 1-Nov-1994.Nadler R, Catalona W, Hudson M and Ratliff T (2018) Durability of the Tumor-Free Response for Intravesical Bacillus Calmette-Guerin TherapyJournal of Urology, VOL. 152, NO. 2 Part 1, (367-373), Online publication date: 1-Aug-1994.Sarosdy M, Hutzler D, Yee D and Von Hoff D (2018) In vitro Sensitivity Testing of Human Bladder Cancers and Cell Lines to TP-40, a Hybrid Protein with selective Targeting and CytotoxicityJournal of Urology, VOL. 150, NO. 6, (1950-1955), Online publication date: 1-Dec-1993.Melekos M, Chionis H, Pantazakos A, Fokaefs E, Paranychianakis G and Dauaher H (2018) Intravesical Bacillus Calmette-Guerin Immunoprophylaxis of Superficial Bladder Cancer: Results of a Controlled Prospective Trial with Modified Treatment ScheduleJournal of Urology, VOL. 149, NO. 4, (744-748), Online publication date: 1-Apr-1993.D'Hallewin M, Baert L, Marijnissen J and Star W (2018) Whole Bladder Wall Photodynamic Therapy with in Situ Light Dosimetry for Carcinoma in Situ of the BladderJournal of Urology, VOL. 148, NO. 4, (1152-1155), Online publication date: 1-Oct-1992.Sarosdy M, Lamm D, Williams R, Moon T, Flanigan R, Crawford E, Wilks N, Earhart R and Merritt J (2018) Phase 1 Trial of Oral Bropirimine in Superficial Bladder CancerJournal of Urology, VOL. 147, NO. 1, (31-33), Online publication date: 1-Jan-1992.Klein E, Rogatko A and Herr H (2018) Management of Local Bacillus Calmette-Guerin Failures in Superficial Bladder CancerJournal of Urology, VOL. 147, NO. 3 Part 1, (601-605), Online publication date: 1-Mar-1992.Morales A, Nickel J and Wilson J (2018) Dose-Response of Bacillus Calmette-Guerin in the Treatment of Superficial Bladder CancerJournal of Urology, VOL. 147, NO. 5, (1256-1258), Online publication date: 1-May-1992.Herr H (2018) Editorial CommentsJournal of Urology, VOL. 147, NO. 5, (1258-1258), Online publication date: 1-May-1992.Lamm D (2018) Editorial CommentsJournal of Urology, VOL. 147, NO. 5, (1258-1258), Online publication date: 1-May-1992.Pagano F, Bassi P, Milani C, Meneghini A, Maruzzi D and Garbeglio A (2018) A Low Dose Bacillus Calmette-Guerin Regimen in Superficial Bladder Cancer Therapy: Is it Effective?Journal of Urology, VOL. 146, NO. 1, (32-35), Online publication date: 1-Jul-1991.Matzkin H, Soloway M and Hardeman S (2018) Transitional Cell Carcinoma of the ProstateJournal of Urology, VOL. 146, NO. 5, (1207-1212), Online publication date: 1-Nov-1991.Herr H (2018) Progression of Stage T1 Bladder Tumors After Intravesical Bacillus Calmette-GuerinJournal of Urology, VOL. 145, NO. 1, (40-43), Online publication date: 1-Jan-1991.Steinberg G, Brendler C, Squire R and Isaacs J (2018) Experimental Intravesical Therapy for Superficial Transitional Cell Carcinoma in a Rat Bladder Tumor ModelJournal of Urology, VOL. 145, NO. 3, (647-653), Online publication date: 1-Mar-1991.Droller M (2018) Editorial CommentsJournal of Urology, VOL. 146, NO. 6, (1512-1513), Online publication date: 1-Dec-1991.Böhle A, Gerdes J, Ulmer A, Hofstetter A and Flad H (2018) Effects of Local Bacillus Calmette-Guerin Therapy in Patients with Bladder Carcinoma on Immunocompetent Cells of the Bladder WallJournal of Urology, VOL. 144, NO. 1, (53-58), Online publication date: 1-Jul-1990.Böhle A, Nowc C, Ulmer A, Musehold J, Gerdes J, Hofstetter A and Flad H (2018) Elevations of Cytokines Interleukin-1, Interleukin-2 and Tumor Necrosis Factor in the Urine of Patients after Intravesical Bacillus Calmette-Guerin ImmunotherapyJournal of Urology, VOL. 144, NO. 1, (59-64), Online publication date: 1-Jul-1990.Brosman S and Lamm D (2018) The Preparation, Handling and Use of Intravesical Bacillus Calmette-Guerin for the Management of Stage Ta, T1, Carcinoma in Situ and Transitional Cell CancerJournal of Urology, VOL. 144, NO. 2 Part 1, (313-315), Online publication date: 1-Aug-1990.Bruce Malkowicz S, Nichols P, Lieskovsky G, Boyd S, Huffman J and Skinner D (2018) The Role of Radical Cystectomy in the Management of High Grade Superficial Bladder Cancer (PA, P1PIS and P2)Journal of Urology, VOL. 144, NO. 3, (641-645), Online publication date: 1-Sep-1990.Coplen D, Marcus M, Myers J, Ratliff T and Catalona W (2018) Long-Term Followup of Patients Treated With 1 or 2, 6-Week Courses of Intravesical Bacillus Calmette-Guerin: Analysis of Possible Predictors of Response Free of TumorJournal of Urology, VOL. 144, NO. 3, (652-657), Online publication date: 1-Sep-1990.Glashan R (2018) A Randomized Controlled Study of Intravesical α−2b-Interferon in Carcinoma in Situ of the BladderJournal of Urology, VOL. 144, NO. 3, (658-661), Online publication date: 1-Sep-1990.Carballido J, Alvarez-Mon M, Solovera J, Menéndez-Ondina L and Durántez A (2018) Clinical Significance of Natural Killer Activity in Patients with Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 143, NO. 1, (29-33), Online publication date: 1-Jan-1990.Bretton P, Herr H, Kimmel M, Whitmore W, Laudone V, Oettgen H and Fair W (2018) The Response of Patients with Superficial Bladder Cancer to a Second Course of Intravesical Bacillus Calmette-GuerinJournal of Urology, VOL. 143, NO. 4, (710-712), Online publication date: 1-Apr-1990.Ratliff T (2018) Editorial CommentsJournal of Urology, VOL. 143, NO. 4, (712-712), Online publication date: 1-Apr-1990.Sarosdy M and Lamm D (2018) Long-Term Results of Intravesical Bacillus Calmette-Guerin Therapy for Superficial Bladder CancerJournal of Urology, VOL. 142, NO. 3, (719-722), Online publication date: 1-Sep-1989.Herr H (2018) Editorial CommentJournal of Urology, VOL. 142, NO. 3, (722-722), Online publication date: 1-Sep-1989.Studer U, Casanova G, Kraft R and Zingg E (2018) Percutaneous Bacillus Calmette-Guerin Perfusion of the Upper Urinary Tract for Carcinoma in SituJournal of Urology, VOL. 142, NO. 4, (975-977), Online publication date: 1-Oct-1989.Catalona W (2018) Editorial CommentsJournal of Urology, VOL. 141, NO. 1, (28-28), Online publication date: 1-Jan-1989.Kim H and Lee C (2018) Intravesical Mitomycin C Instillation as a Prophylactic Treatment of Superficial Bladder TumorJournal of Urology, VOL. 141, NO. 6, (1337-1339), Online publication date: 1-Jun-1989.Hardeman S, Perry A and Soloway M (2018) Transitional Cell Carcinoma of the Prostate Following Intravesical Therapy for Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 140, NO. 2, (289-292), Online publication date: 1-Aug-1988.Pauwels R, Schapers R, Smeets A, Jansen L, Debruyne F and Geraedts J (2018) Blood Group Isoantigen Deletion and Chromosomal Abnormalities in Bladder CancerJournal of Urology, VOL. 140, NO. 5 Part 1, (959-963), Online publication date: 1-Nov-1988.Torrence R, Kavoussi L, Catalona W and Ratliff T (2018) Prognostic Factors in Patients Treated with Intravesical Bacillus Calmette-Guerin for Superficial Bladder CancerJournal of Urology, VOL. 139, NO. 5, (941-944), Online publication date: 1-May-1988. Volume 137Issue 2February 1987Page: 220-224 Advertisement Copyright & Permissions© 1987 by The American Urological Association Education and Research, Inc.MetricsAuthor Information William J. Catalona More articles by this author M'liss A. Hudson More articles by this author Daniel P. Gillen More articles by this author Gerald L. Andriole More articles by this author Timothy L. Ratliff More articles by this author Expand All Advertisement Loading ...